The FDA has approved AstraZeneca's Seroquel (quetiapine fumarate tablets) for the maintenance treatment of patients with bipolar I disorder, as adjunct therapy to lithium or divalproex.

Revolution Health and EmergingMed announced a partnership to offer a new cancer clinical trial matching service for patients and physicians.

Pfizer named Garry Nicholson SVP, general manager of the company's newly created Oncology Business Unit with direct responsibility for clinical development, medical affairs, commercial development, sales and marketing.

Bristol-Myers Squibb and KAI Pharmaceuticals, a privately held biotechnology company, have announced an exclusive agreement for the global development and commercialization of KAI-9803.

The FDA approved Novo Nordisk's NovoSeven RT (coagulation factor VIIa [recombinant] room temperature stable), the first room temperature stable recombinant product available for the treatment of bleeding episodes in patients with hemophilia with inhibitors.

Eli Lilly announced that the FDA has approved Strattera (atomoxetine HCI) for maintenance treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents.

The FDA approved GlaxoSmithKline's Advair Diskus 250/50 (fluticasone propionate 250 mcg and salmeterol 50 mcg inhalation powder) for the reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD).

Juice Pharma Advertising has partnered with Worldwide Partners, Inc., a global network of independent advertising firms.

The FDA, in partnership with Duke University, announced the executive board for its Clinical Trials Transformation Initiative.

Rep. Anna Eshoo (D-CA) and Rep. Joe Barton (R-TX) have introduced legislation that would create a regulatory pathway for the FDA to approve follow-on or generic biologics.